Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update

Heron Therapeutics, Inc. (NASDAQ:HRTX) was the recipient of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 28,810,000 shares, a drop of 6.0% from the October 15th total of 30,640,000 shares. Based on an average trading volume of 1,830,000 shares, the days-to-cover ratio is presently 15.7 days.

Hedge Funds Weigh In On Heron Therapeutics

Several large investors have recently added to or reduced their stakes in HRTX. nVerses Capital LLC bought a new position in shares of Heron Therapeutics in the second quarter worth approximately $27,000. HB Wealth Management LLC bought a new position in shares of Heron Therapeutics in the second quarter worth approximately $35,000. Cutter & CO Brokerage Inc. bought a new position in shares of Heron Therapeutics in the third quarter worth approximately $39,000. Y Intercept Hong Kong Ltd bought a new position in shares of Heron Therapeutics in the third quarter worth approximately $39,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics in the second quarter worth approximately $41,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on HRTX shares. StockNews.com raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC dropped their price target on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Heron Therapeutics Trading Up 1.7 %

HRTX opened at $1.19 on Wednesday. The company has a market cap of $181.00 million, a price-to-earnings ratio of -6.61 and a beta of 1.81. The company’s 50 day moving average is $1.80 and its 200 day moving average is $2.49. Heron Therapeutics has a 12-month low of $1.04 and a 12-month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $36.40 million. During the same period in the previous year, the business posted ($0.17) EPS. As a group, analysts predict that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.